{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00919958",
      "OrgStudyIdInfo": {
        "OrgStudyId": "PLX-PAD 1202-1"
      },
      "Organization": {
        "OrgFullName": "Pluristem Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia",
      "OfficialTitle": "Phase I Study of Intramuscular (IM) Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-like Stromal Cells Derived From a Full Term Placenta. These Placental Adherent Stromal Cells (ASCs) Are Expanded in the Company's Proprietary PluriXTM 3D Bioreactor System. PLX Cells Are Immune Privileged and Possess Immunomodulatory Properties."
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2012",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 2009"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2012",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2012",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "June 10, 2009",
      "StudyFirstSubmitQCDate": "June 11, 2009",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 12, 2009",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 17, 2012",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 19, 2012",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Pluristem Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The The purpose of this study is to determine the safety of PLX-PAD single dose, Intra-muscular injection for the treatment of CLI patients.",
      "DetailedDescription": "PLX-PAD are mesenchymal-like stromal cells derived from a full term placenta, termed PLX-PAD, and intended for the treatment of Critical Limb Ischemia"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Peripheral Artery Disease",
          "Peripheral Vascular Disease",
          "Critical Limb Ischemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Peripheral Artery Disease",
          "Peripheral Vascular Disease",
          "Critical limb ischemia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Factorial Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "PLX-PAD low dose",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: PLX-PAD IM injection"
              ]
            }
          },
          {
            "ArmGroupLabel": "PLX-PAD intermediate dose",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: PLX-PAD IM injection"
              ]
            }
          },
          {
            "ArmGroupLabel": "PLX-PAD high dose",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: PLX-PAD IM injection"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "PLX-PAD IM injection",
            "InterventionDescription": "Single treatment; multiple injections",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "PLX-PAD high dose",
                "PLX-PAD intermediate dose",
                "PLX-PAD low dose"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse events, Safety laboratory values and ECG findings",
            "PrimaryOutcomeTimeFrame": "3 months"
          },
          {
            "PrimaryOutcomeMeasure": "Immunological reaction",
            "PrimaryOutcomeTimeFrame": "1 month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Tumorigenesis",
            "SecondaryOutcomeTimeFrame": "24 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of critical limb ischemia defined as persistent, recurring ischemic rest pain for at least two (2) weeks, and/or ulceration or gangrene of the foot or toe, with ABI < 0.4 or/and TBI < 0.4 or transcutaneous partial pressure of oxygen ≤ 30 mmHg pO2 at the foot.\nRutherford category 4-5\nNo acceptable options for re-vascularisation as confirmed by angiographic imaging results or by color flow duplex ultrasound obtained within 6 months prior screening visit and signed approval of vascular surgeon.\nIn the opinion of the investigator, major amputation is not anticipated over a period of three (3) months.\n\nExclusion Criteria:\n\nUncontrolled hypertension (defined as diastolic blood pressure > 110 mmHg or systolic blood pressure > 180 mmHg during screening).\nPoorly controlled diabetes mellitus (HbA1c > 9%)\nWounds with severity greater than Grade 2 on the Wagner Scale\nLife-threatening ventricular arrhythmia - except if an ICD is implanted - or unstable angina pectoris - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged\nST segment elevation myocardial infarction and/or TIA/CVA within six (6) months prior to enrollment. Patients with severe congestive heart failure (i.e. NYHA Stage IV)\nIn the opinion of the investigator, the patient is unsuitable for cellular therapy.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "40 Years",
      "MaximumAge": "81 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Prof. Carsten Tschöpe, MD",
            "OverallOfficialAffiliation": "Charite University, Berlin, Germany",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Franziskus-Krankenhaus",
            "LocationCity": "Berlin",
            "LocationCountry": "Germany"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000014652",
            "ConditionMeshTerm": "Vascular Diseases"
          },
          {
            "ConditionMeshId": "D000058729",
            "ConditionMeshTerm": "Peripheral Arterial Disease"
          },
          {
            "ConditionMeshId": "D000016491",
            "ConditionMeshTerm": "Peripheral Vascular Diseases"
          },
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000050197",
            "ConditionAncestorTerm": "Atherosclerosis"
          },
          {
            "ConditionAncestorId": "D000001161",
            "ConditionAncestorTerm": "Arteriosclerosis"
          },
          {
            "ConditionAncestorId": "D000001157",
            "ConditionAncestorTerm": "Arterial Occlusive Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafAsFound": "Vascular Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M28366",
            "ConditionBrowseLeafName": "Peripheral Arterial Disease",
            "ConditionBrowseLeafAsFound": "Peripheral Artery Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18046",
            "ConditionBrowseLeafName": "Peripheral Vascular Diseases",
            "ConditionBrowseLeafAsFound": "Peripheral Vascular Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M25341",
            "ConditionBrowseLeafName": "Atherosclerosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3621",
            "ConditionBrowseLeafName": "Arteriosclerosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3617",
            "ConditionBrowseLeafName": "Arterial Occlusive Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}